Premium
Oral piretanide in chronic renal failure.
Author(s) -
Henderson IS,
Beattie TJ,
Kennedy AC,
Dombey SL
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb02049.x
Subject(s) - bumetanide , diuresis , diuretic , natriuresis , medicine , creatinine , renal function , furosemide , pharmacology , urology , uric acid , endocrinology , chemistry , sodium , cotransporter , organic chemistry
1 The effects of high doses of piretanide, a new diuretic agent chemically related to frusemide and bumetanide were evaluated in twelve patients with severe chronic renal insufficiency (creatinine clearance below 25 ml/min). 2 Patients received either 30 mg or 60 mg piretanide orally after a water load of 11. Urine volume and the excretion of electrolytes, creatinine, urea and uric acid were measured over the subsequent 24 h. 3 Piretanide produced an effective diuresis and natriuresis in these patients, its action being broadly similar to those of bumetanide and frusemide observed in previous studies.